Botulinum Toxin Type A for Therapeutic Use from Canada
Purified botulinum toxin type A complex, indicated for cervical dystonia and spasticity management. Falls under HTS 3002.90.52.50 as a toxin prepared for therapeutic use, a culture-derived product modulating neuromuscular transmission. Used in measured doses for neurological conditions.
Duty Rate — Canada → United States
0%
Rate breakdown
9903.05.860%Universal product exemption (U.S. note 52(b))
Import Tips
• Include potency bioassay results in LD50 units for FDA clearance
• Refrigerated transport required; monitor for 2-8°C compliance
• Distinguish from cosmetic uses which may fall under medicaments